Background: Ganciclovir is the mainstay of therapy for the prophylaxis and treatment of
Cytomegalovirus. However, therapy with this antiviral agent is hindered by side effects such …

Ganciclovir and valganciclovir are first choice drugs for the prevention and treatment of
cytomegalovirus infection and disease in solid organ and stem cell transplant recipients …

Abstract The Practice Guidelines Committee of the American Society of Transplantation and
Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID …

Background: Ganciclovir and valganciclovir are used for prophylaxis and treatment of
cytomegalovirus infection. However, there is great interindividual variability in ganciclovir's …

Abstract Development of new approaches for oral delivery of an existing antiviral drug aimed
to enhance its permeability and hence bioavailability. Ganciclovir (GC) is an antiviral drug …

Pediatric organ transplant recipients have many of the same infectious complications as
adults solid organ transplant (SOT) recipients. However, key differences exist in the …

Evidence supporting the use of therapeutic drug monitoring o... : Current Opinion in Infectious
Diseases Evidence supporting the use of therapeutic drug monitoring of ganciclovir in …

Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ
transplantation. This high burden of disease, which incurs sizeable morbidity, may be …

Background Valganciclovir is the first‐line agent for Cytomegalovirus prophylaxis after lung
transplantation. However, its use is associated with a relatively high risk of hematological …

The aim of this prospective study was to evaluate the pharmacokinetics of ganciclovir in lung
transplant recipients, to explore its covariates, and to propose an individualized dosing …